CIM
REGN icon

Cambria Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cambria Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
830
+475
+134% +$323K 0.03% 506
2026
Q1 		$274K Sell
355
-170
-32% -$130K 0.02% 539
2025
Q4 		$405K Sell
525
-2,565
-83% -$1.74M 0.02% 442
2025
Q3 		$1.74M Buy
3,090
+554
+22% +$313K 0.11% 170
2025
Q2 		$1.33M Buy
+2,536
New +$1.42M 0.09% 182

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cambria Investment Management's REGN Position: Q2 2026 in Review

Cambria Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 134% in Q2 2026, buying an estimated $323K and bringing the position to 830 shares worth $518K. The position accounts for 0.03% of the portfolio, ranked #506.

Cambria Investment Management first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.74M in Q3 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cambria Investment Management held 830 shares of Regeneron Pharmaceuticals worth $518K as of Q2 2026.
  • Cambria Investment Management bought 475 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $323K.
  • Regeneron Pharmaceuticals made up 0.03% of Cambria Investment Management's portfolio in Q2 2026, its #506 holding.
  • Cambria Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Cambria Investment Management's Regeneron Pharmaceuticals position peaked at $1.74M in Q3 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.